{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T06:27:55Z","timestamp":1787120875245,"version":"build-2736575974"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019081","name":"Science and Technology Program of Hunan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019081","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Proton pump inhibitors (PPIs) are the first-line therapy for acid-related disorders, with particularly high rates of chronic use in adults aged \u226565\u00a0years. Nearly all existing studies treat PPIs as a uniform drug class, overlooking potential heterogeneity in fracture risk across individual agents. This study aimed to evaluate the relative fracture risk of individual PPIs in elderly adults, using a complementary dual-method approach of network meta-analysis (NMA) and disproportionality analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>First, we performed a NMA to compare the relative risk of any-site fracture associated with individual PPIs. Second, we performed a complementary disproportionality analysis using data from the US FDA Adverse Event Reporting System (FAERS) database, with additional analysis of osteoporosis\/osteopenia events defined by the Standardised Medical Dictionary for Regulatory Activities (MedDRA) Standardised Query (SMQ).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The NMA included 9 eligible studies, enrolling a total of 257,445 participants. Compared with non-PPI users, omeprazole (OR 1.51, 95%CI 1.36\u20131.67), rabeprazole (OR 1.47, 95%CI 1.22\u20131.78), pantoprazole (OR 1.44, 95%CI 1.28\u20131.62), and lansoprazole (OR 1.32, 95%CI 1.14\u20131.53) were associated with a significantly increased risk of any-site fracture. In contrast, esomeprazole showed no significant association with overall fracture risk (OR 1.16, 95%CI 0.97\u20131.38). Pairwise comparisons from the NMA showed that esomeprazole had a lower relative fracture risk compared with other individual PPIs. In the FAERS analysis, we identified 16,908 PPI-related fracture adverse events. Consistent with NMA findings, omeprazole exhibited a significant fracture risk signal (ROR 1.25, 95%CI 1.03\u20131.51), while esomeprazole showed no significant signal for overall fracture (ROR 0.89, 95%CI 0.66\u20131.20). However, esomeprazole presented a strong positive risk signal in the narrow-scope MedDRA SMQ analysis for Osteoporosis\/Osteopenia (ROR 2.44, 95%CI 1.41\u20134.20).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Long-term PPI use is associated with increased fracture risk in elderly adults, with significant heterogeneity in bone safety profiles across individual PPI agents. Although esomeprazole was not significantly associated with fracture risk in NMA or FAERS fracture analyses, it showed a strong narrow-scope osteoporosis\/osteopenia SMQ signal. This discordance indicates that absence of a fracture signal should not imply skeletal safety. These findings provide evidence-based guidance for individualized PPI prescribing in elderly patients, with careful benefit-risk assessment for those requiring extended-duration PPI regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1835602","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:47:45Z","timestamp":1787118465000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Differential fracture risk among proton pump inhibitors in older adults: evidence network and pharmacovigilance validation"],"prefix":"10.3389","volume":"17","author":[{"given":"Hui-ling","family":"Piao","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Third Xiangya Hospital of Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeng-hao","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third Xiangya Hospital of Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-yun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third Xiangya Hospital of Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-hong","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third Xiangya Hospital of Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-yao","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third Xiangya Hospital of Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-jun","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third Xiangya Hospital of Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-hu","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, The Second Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"B48","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.annepidem.2014.01.004","article-title":"Proton-pump inhibitor use and hip fractures in men: a population-based case-control study","volume":"24","author":"Adams","year":"2014","journal-title":"Ann. Epidemiol."},{"key":"B1","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.47391\/jpma.22742","article-title":"Long-term use of proton pump inhibitors (PPIs) and their effects on bone health","volume":"75","author":"Ahmad","year":"2025","journal-title":"J. Pak Med. Assoc."},{"key":"B2","doi-asserted-by":"publisher","first-page":"100732","DOI":"10.1016\/j.bonr.2020.100732","article-title":"Effect of proton pump inhibitors on bone mineral density: a systematic review and meta-analysis of observational studies","volume":"13","author":"Aleraij","year":"2020","journal-title":"Bone Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/pds.885","article-title":"Disproportionality analysis using empirical bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting","volume":"12","author":"Almenoff","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B4","doi-asserted-by":"publisher","first-page":"E170","DOI":"10.9778\/cmajo.20210240","article-title":"Prescribing, deprescribing and potential adverse effects of proton pump inhibitors in older patients with multimorbidity: an observational study","volume":"11","author":"Aubert","year":"2023","journal-title":"CMAJ Open"},{"key":"B5","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00774-015-0699-6","article-title":"Esomeprazole use is independently associated with significant reduction of BMD: 1-Year prospective comparative safety study of four proton pump inhibitors","volume":"34","author":"Bahtiri","year":"2016","journal-title":"J. Bone Mineral Metabolism"},{"key":"B6","first-page":"8893","article-title":"Acid-suppressive medications and risk of fracture: an updated meta-analysis","volume":"8","author":"Cai","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/phar.1410","article-title":"Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting","volume":"34","author":"Cea Soriano","year":"2014","journal-title":"Pharmacotherapy"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e90627","DOI":"10.7759\/cureus.90627","article-title":"Long-term proton pump inhibitor use and the risk of kidney disease, dementia, and fractures: a systematic review","volume":"17","author":"Chaudhry","year":"2025","journal-title":"Cureus"},{"key":"B9","doi-asserted-by":"publisher","first-page":"13501","DOI":"10.3390\/ijerph192013501","article-title":"Increased risk of fractures and use of proton pump inhibitors in menopausal women: a systematic review and meta-analysis","volume":"19","author":"Da Maia","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.blre.2015.03.004","article-title":"Antithrombotic drugs, patient characteristics, and gastrointestinal bleeding: clinical translation and areas of research","volume":"29","author":"DI Minno","year":"2015","journal-title":"Blood Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","article-title":"The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American gastroenterological association","volume":"152","author":"Freedberg","year":"2017","journal-title":"Gastroenterology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1111\/bcp.15847","article-title":"Different effects of chronic omeprazole use on osteoporotic fractures rate in the elderly","volume":"89","author":"Gingold-Belfer","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/pds.4406","article-title":"Proton pump inhibitor use and the risk of fractures among an older adult cohort","volume":"27","author":"Harding","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.3109\/13880209.2014.892141","article-title":"Effects of calcitriol on bone mineral density in patients treated with esomeprazole","volume":"52","author":"Huang","year":"2014","journal-title":"Pharm. Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/m14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1742-7843.2006.pto_378.x","article-title":"Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas","volume":"98","author":"Jensen","year":"2006","journal-title":"Basic and Clinical Pharmacology and Toxicology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1001\/jama.2015.13766","article-title":"Trends in prescription drug use among adults in the United States from 1999-2012","volume":"314","author":"Kantor","year":"2015","journal-title":"Jama"},{"key":"B19","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.bone.2010.12.015","article-title":"Meta-analysis: risk of fractures with acid-suppressing medication","volume":"48","author":"Kwok","year":"2011","journal-title":"Bone"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1111\/apt.16008","article-title":"Proton pump inhibitors increase risk of bone fractures in men with cirrhosis: a population-based study","volume":"52","author":"Labenz","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1007\/s00535-012-0722-9","article-title":"A population-based case\u2013control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate","volume":"48","author":"Lee","year":"2013","journal-title":"J. Gastroenterol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.lfs.2018.12.058","article-title":"Proton pump inhibitors therapy and risk of bone diseases: an update meta-analysis","volume":"218","author":"Liu","year":"2019","journal-title":"Life Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e040473","DOI":"10.1136\/bmjopen-2020-040473","article-title":"Proton pump inhibitor utilisation and potentially inappropriate prescribing analysis: insights from a single-centred retrospective study","volume":"10","author":"Liu","year":"2020","journal-title":"BMJ Open"},{"key":"B23","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1053\/j.gastro.2019.05.056","article-title":"Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.11005\/jbm.2018.25.3.141","article-title":"Proton-pump inhibitor use and fracture risk: an updated systematic review and meta-analysis","volume":"25","author":"Nassar","year":"2018","journal-title":"J. Bone Metab."},{"key":"B11","article-title":"Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management","year":"2019","journal-title":"NICE Guideline CG184"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/ajg.2011.113","article-title":"Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies","volume":"106","author":"Ngamruengphong","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3389\/fphar.2019.01319","article-title":"Review of statistical methodologies for detecting drug-drug interactions using spontaneous reporting systems","volume":"10","author":"Noguchi","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","article-title":"Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery","volume":"22","author":"Nor\u00e9n","year":"2013","journal-title":"Stat. Methods Med. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1007\/s00296-013-2709-0","article-title":"Bone density in proton pump inhibitors users: a prospective study","volume":"33","author":"Ozdil","year":"2013","journal-title":"Rheumatol. Int."},{"key":"B29","doi-asserted-by":"publisher","first-page":"105714","DOI":"10.1016\/j.jbspin.2024.105714","article-title":"Proton pump inhibitors, bone and phosphocalcic metabolism","volume":"91","author":"Philippoteaux","year":"2024","journal-title":"Jt. Bone Spine"},{"key":"B30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00198-018-4788-y","article-title":"Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies","volume":"30","author":"Poly","year":"2019","journal-title":"Osteoporos. Int."},{"key":"B31","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.bone.2012.09.028","article-title":"Use of proton pump inhibitors and risk of fragility hip fracture in a mediterranean region","volume":"52","author":"Reyes","year":"2013","journal-title":"Bone"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1016\/j.clinthera.2023.11.011","article-title":"Magnitude and determinants of long-term use of proton pump inhibitors among Portuguese older adults in primary health care","volume":"46","author":"Rodrigues","year":"2024","journal-title":"Clin. Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40264-021-01082-y","article-title":"Reporting of thromboembolic events with JAK inhibitors: analysis of the FAERS database 2010-2019","volume":"44","author":"Setyawan","year":"2021","journal-title":"Drug Saf."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00228-023-03534-z","article-title":"Proton pump inhibitor use: systematic review of global trends and practices","volume":"79","author":"Shanika","year":"2023","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s00223-021-00882-9","article-title":"Proton pump inhibitors inhibit PHOSPHO1 activity and matrix mineralisation in vitro","volume":"109","author":"Staines","year":"2021","journal-title":"Calcif. Tissue Int."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.3390\/ijerph16091571","article-title":"Proton pump inhibitors and fracture risk: a review of current evidence and mechanisms involved","volume":"16","author":"Thong","year":"2019","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/apt.14589","article-title":"Proton pump inhibitor use and risk of hip fractures among community-dwelling persons with Alzheimer's disease-a nested case-control study","volume":"47","author":"Torvinen-Kiiskinen","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.26442\/20751753.2024.1.202532","article-title":"Cardiovascular risk with long-term use of proton pump inhibitors: myth or reality. A review","volume":"26","author":"Trukhan","year":"2024","journal-title":"Cons. Medicum."},{"key":"B39","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.bone.2015.08.024","article-title":"The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: a prospective cohort study","volume":"81","author":"Van Der Hoorn","year":"2015","journal-title":"Bone"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B41","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s00223-006-0021-7","article-title":"Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture","volume":"79","author":"Vestergaard","year":"2006","journal-title":"Calcif. Tissue Int."},{"key":"B42","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s40264-022-01200-4","article-title":"A disproportionality analysis of drug-drug interactions of tizanidine and CYP1A2 inhibitors from the FDA adverse event reporting system (FAERS)","volume":"45","author":"Villa-Zapata","year":"2022","journal-title":"Drug Saf."},{"key":"B43","volume-title":"The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in meta-analyses","author":"Wells","year":"2013"},{"key":"B44","doi-asserted-by":"publisher","first-page":"237","DOI":"10.18433\/jpps32867","article-title":"Torsade de Pointes\/QT Prolongation Associated with Antifungal Triazoles: a Pharmacovigilance Study Based on the U.S. FDA Adverse Event Reporting System (FAERS)","volume":"25","author":"Yu","year":"2022","journal-title":"J. Pharm. Pharm. Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US food and drug administration adverse events reporting system","volume":"7","author":"Zhai","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00198-015-3365-x","article-title":"Proton-pump inhibitors and risk of fractures: an update meta-analysis","volume":"27","author":"Zhou","year":"2016","journal-title":"Osteoporos. Int."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1835602\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:47:46Z","timestamp":1787118466000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1835602\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":48,"alternative-id":["10.3389\/fphar.2026.1835602"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1835602","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"1835602"}}